Cart
sales@molnova.com
ICA-105574
CAS No. 316146-57-3
ICA-105574 ( ICA; 3-nitro-N-[4-phenoxyphenyl]-benzamide )
Catalog No. M24250 CAS No. 316146-57-3
ICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 76 | In Stock |
|
| 10MG | 132 | In Stock |
|
| 25MG | 282 | In Stock |
|
| 50MG | 444 | In Stock |
|
| 100MG | 651 | In Stock |
|
| 500MG | 1368 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameICA-105574
-
NoteResearch use only, not for human use.
-
Brief DescriptionICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
-
DescriptionICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
-
SynonymsICA; 3-nitro-N-[4-phenoxyphenyl]-benzamide
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorhERG
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number316146-57-3
-
Formula Weight334.3
-
Molecular FormulaC19H14N2O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESC1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)C3=CC(=CC=C3)[N+](=O)[O-]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Meng J , Shi C , Li L , et al. Compound ICA-105574 prevents arrhythmias induced by cardiac delayed repolarization[J]. European Journal of Pharmacology, 2013, 718(1-3):87-97.
molnova catalog
related products
-
AEE-788
A potent, orally bioavailable dual EGFR/VEGFR receptor tyrosine kinase inhibitor with IC50 of 2, 6, 77 and 59 nM for EGFR, ErbB2, KDR and Flt-1, respectively.
-
Theliatinib
Theliatinib a potent and highly selective EGFR inhibitor with anti-tumor activity. Ki of 0.05 nM for wild type EGFR and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant respectively.
-
Panitumumab
Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
